Guest guest Posted January 30, 2004 Report Share Posted January 30, 2004 it was the one with the picture of the nurse on it. I copied the two sections I was refering to for you. Ameta-analysis of three clinical studies of glatiramer acetate has reported a one-third reduction in relapses over the two-year study period. The median time to a first relapse was 322 days with glatiramer acetate compared to 219 days with placebo. ("Median" means that one-half of the people had a relapse before that time point and one-half had it after.) Greater disability and a higher relapse rate prior to the study were the best predictors of relapse rate while on treatment. It has not been determined if a reduction in relapse rate lowers the risk of disability beyond the first two years of therapy. The study was first presented by Dr. Jerry Wolinsky and colleagues at the April meeting of the American Academy of Neurology (see the last issue of Dialog, vol. 4, no. 2), and was published in the August issue of the journal Multiple Sclerosis Canadian neurologist Dr. Rice of London, Ontario, and European researchers have questioned whether beta-interferons used to treat relapsing-remitting MS are effective after one year of treatment (Lancet, vol. 361, pp. 545-552, 2003). Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.